Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Inactivated Enterovirus Type 71 Vaccine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1: 200U EV71 vaccine | EXPERIMENTAL | 12 adults received 3 doses of 200U EV71 vaccine 14 days apart |
| Group 2: 400U EV71 vaccine | EXPERIMENTAL | 12 adults received 3 doses of 400U EV71 vaccine 14 days apart |
| Group 1: Placebo | PLACEBO_COMPARATOR | 6 adults received 3 doses of placebo 14 days apart |
| Group 2: Placebo | PLACEBO_COMPARATOR | 6 adults received 3 doses of placebo 14 days apart |
| Name | Type | Description |
|---|---|---|
| Inactivated Enterovirus Type 71 Vaccine | BIOLOGICAL | A Sinovac EV71 vaccine contains inactivated EV71 virus, aluminum hydroxide, sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate and injection water. The EV71 vaccine is supplied in one mono-dose vial containing 0.5 mL of viral suspension with EV71 virus antigen of 200U and 400U (Elisa unit) |
| Placebo | OTHER | Placebo is suspension with a little ivory precipitation, composition of which is aluminum hydroxide diluents. |
Inclusion Criteria: 1. Healthy males and females, aged from 18 to 49 years old. Health is determined by medical history, physical examination, laboratory examination and clinical judgment of the investigator 2. Provided legal identification for the sake of recruitment. 3. Subjects are able to under...
Inactivated Enterovirus Type 71 Vaccine is used for the prevention of infection caused by enterovirus type 71, which is a viral infection. It is being developed as a vaccine to protect against this viral pathogen, which can cause hand, foot, and mouth disease and potentially severe neurological complications.
Inactivated Enterovirus Type 71 Vaccine is being developed by Sinovac Biotech, Ltd, a biopharmaceutical company. The company's ticker symbol is SVA. Sinovac Biotech is conducting clinical trials to evaluate the safety and efficacy of this vaccine candidate.
Inactivated Enterovirus Type 71 Vaccine is currently in Phase 1 clinical development. It is an investigational vaccine that has not yet been approved by regulatory authorities. The Phase 1 trial has been completed, and the vaccine is still in the early stages of clinical testing.
Inactivated Enterovirus Type 71 Vaccine has one completed clinical trial with the identifier NCT01273233. The trial was titled 'Safety of an Inactivated Enterovirus Type 71 Vaccine in Healthy Adults' and was a Phase 1, randomized, double-blind, placebo-controlled study conducted in China with 36 healthy adult participants.
Inactivated Enterovirus Type 71 Vaccine is a specific vaccine candidate developed by Sinovac Biotech. It is an inactivated vaccine, meaning it contains killed virus particles. There are other enterovirus vaccines in development, but this particular vaccine is distinct and is being evaluated in its own clinical trial program.